Based on the Burning Rock Biotech Ltd stock forecast from 0 analysts, the average analyst target price for Burning Rock Biotech Ltd is not available over the next 12 months. Burning Rock Biotech Ltd’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Burning Rock Biotech Ltd is Bearish, which is based on 2 positive signals and 7 negative signals. At the last closing, Burning Rock Biotech Ltd’s stock price was USD 3.60. Burning Rock Biotech Ltd’s stock price has changed by +28.11% over the past week, -4.00% over the past month and +256.44% over the last year.
No recent analyst target price found for Burning Rock Biotech Ltd
No recent average analyst rating found for Burning Rock Biotech Ltd
Company Overview Burning Rock Biotech Ltd
Burning Rock Biotech Limited primarily develops and sells cancer therapy selection tests in the People's Republic of China. It operates through three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoCompass IO, a corresponding test for liquid biopsy samples; OncoScreen IO, a pan-cancer test for tissue samples; and OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC. The company also provides ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and brPROPHET, a pre-operative ctDNA detection and post-operative MRD calling for relapsed patients, as well as Magnis BR-customized version of its principal products. In addition, it offers OncoMaster, an automatic NGS data analysis and report interpretation machine for in-hospital model. Burning Rock Biotech Limited has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; and collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, IMPACT Therapeutics, Boehringer Ingelheim, and Merck KGaA. The company was founded in 2014 and is headquartered in Guangzhou, the People's Republic of China. Read Less
Burning Rock Biotech Limited primarily develops and sells cancer therapy selection tests in the People's Republic of China. It operates through three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily o...Read More
Frequently Asked Questions About Burning Rock Biotech Ltd (BNR) Stock
Stock Target Advisor's fundamental analysis for Burning Rock Biotech Ltd's stock is Bearish.
Unfortunately we do not have enough data on BNR's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on BNR's stock to indicate what its average analyst target is.
BNR stock's Price/Earning ratio is 76.32.
Our analysis grades BNR stock's Price / Earning ratio at F. This means that BNR stock's Price/Earning ratio is above 74% of the stocks in the Diagnostics & Research sector in the NSD exchange.
Based on this BNR may be a overvalued for its sector.
The last closing price of BNR's stock was USD 3.60.
The most recent market capitalization for BNR is USD 0.03B.
Unfortunately we do not have enough analyst data on BNR's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Burning Rock Biotech Ltd's stock.
As per our most recent records Burning Rock Biotech Ltd has 786 Employees.
Burning Rock Biotech Ltd's registered address is No. 5, Xingdao Ring Road North, Guangzhou, China, 510005.
You can get more information about it from Burning Rock Biotech Ltd's website at https://www.brbiotech.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
What not to like
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Burning Rock Biotech Ltd (BNR) Stock
Stock Target Advisor's fundamental analysis for Burning Rock Biotech Ltd's stock is Bearish.
Unfortunately we do not have enough data on BNR's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on BNR's stock to indicate what its average analyst target is.
BNR stock's Price/Earning ratio is 76.32.
Our analysis grades BNR stock's Price / Earning ratio at F. This means that BNR stock's Price/Earning ratio is above 74% of the stocks in the Diagnostics & Research sector in the NSD exchange.
Based on this BNR may be a overvalued for its sector.
The last closing price of BNR's stock was USD 3.60.
The most recent market capitalization for BNR is USD 0.03B.
Unfortunately we do not have enough analyst data on BNR's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Burning Rock Biotech Ltd's stock.
As per our most recent records Burning Rock Biotech Ltd has 786 Employees.
Burning Rock Biotech Ltd's registered address is No. 5, Xingdao Ring Road North, Guangzhou, China, 510005.
You can get more information about it from Burning Rock Biotech Ltd's website at https://www.brbiotech.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for BNR !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
